Skip to main content

Table 1 Demographics and baseline clinical and migraine characteristics

From: Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

 

Eptinezumab 300 mg

N = 128

Demographics

 Mean (SD) age, years

41.5 (11.33)

 Sex, n (%)

  Male

19 (14.8)

  Female

109 (85.2)

 Ethnicity, n (%)

  Hispanic or Latino

26 (20.3)

  Not Hispanic or Latino

102 (79.7)

 Race, n (%)

  White

122 (95.3)

  Black or African American

4 (3.1)

  Asian

1 (<1)

  Multiple Races

1 (<1)

Clinical characteristics

 Mean (SD) weight, kg

77.8 (16.97)

 Mean (SD) height, cm

166.3 (9.01)

 Mean (SD) BMI, kg/m2

28.0 (5.07)

Migraine history

 Mean (SD) age at migraine diagnosis, years

20.4 (8.94)

 Mean (SD) duration of migraine diagnosis, years

21.2 (11.65)

 Mean (SD) number of years with CM

13.5 (11.11)

 MOH diagnosis, n (%)

49 (38.3)

 Mean (SD) number of headache daysa

20.3 (3.68)

 Mean (SD) number of migraine daysa

14.1 (4.25)

 Mean (SD) number of migraine attacksa

10.5 (4.29)

 Most bothersome symptom, n (%)b

 

 Sensitivity to light

31 (24.2)

 Pain

21 (16.4)

 Nausea/vomiting

17 (13.3)

 Pain – with activity

11 (8.6)

 Sensitivity to sound

11 (8.6)

 Throbbing/pulsation

8 (6.3)

 Headache

4 (3.1)

 Vision impacts

4 (3.1)

 Cognitive disruption

5 (3.9)

 Multiple

3 (2.3)

 Pain – anatomical

3 (2.3)

 Aura

2 (1.6)

 Dizziness

2 (1.6)

 Mood changes

2 (1.6)

 Allodynia

1 (<1)

 Eye pain

1 (<1)

 Neck pain

1 (<1)

 Speech difficulty

1 (<1)

Concomitant headache medicationsc

 Used ≥1 acute headache medication, n (%)

127 (99.2)

  Thomapyrin N

57 (44.5)

  Ibuprofen

52 (40.6)

  Sumatriptan

43 (33.6)

  Paracetamol

26 (20.3)

  Naproxen sodium

13 (10.2)

 Used ≥1 prophylactic medication, n (%)

46 (35.9)

  Topiramate

16 (12.5)

  1. BMI Body mass index, CM Chronic migraine, MOH Medication-overuse headache, SD Standard deviation. aSelf-reported average number per 28-day period in the 3 months prior to screening. bDistribution of most bothersome symptom after post hoc medical review to recode “other” symptoms identified by patients at screening. cMedications with a start or stop date on or after the treatment dosing date are considered concomitant